Saturday 17 October 2026
Export VCEL’s income statement to Excel — free account
Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
40.13
0.89
−2.17%
Follow VCEL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
92.69 | 74.81 | 112.53 | 121.04 |
+8 more quarters Free account |
P/S ratio |
7.42 | 5.59 | 6.56 | 6.14 | |
P/FCF ratio |
36.85 | 34.40 | 73.25 | 77.98 | |
P/Operating CF |
140.35 | 99.70 | 120.74 | 71.95 | |
P/B ratio |
6.14 | 4.59 | 5.11 | 4.94 | |
Price to Tangible BV |
6.23 | 4.66 | 5.19 | 5.03 | |
EV/Sales |
6.94 | 5.15 | 6.13 | 5.68 | |
EV/EBITDA |
68.01 | 53.72 | 74.82 | 87.03 | |
EV/Operating CF |
30.53 | 24.40 | 32.61 | 24.87 | |
EV/FCF |
34.50 | 31.70 | 68.39 | 72.18 | |
Quick Ratio |
4.53 | 4.62 | 4.52 | 4.30 | |
Current Ratio |
5.04 | 5.18 | 5.03 | 4.87 | |
Net Debt/EBITDA |
(40.05) | 30.47 | (5.37) | (21.23) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.65 | 0.64 | 0.60 | 0.61 | |
Operating CF/Net income |
7.34 | (2.60) | 0.65 | 4.35 | |
Capex/Depreciation |
(0.53) | (0.38) | (0.68) | (0.90) | |
Interest Coverage |
2.71 | (50.40) | 138.36 | 21.84 | |
Research and Development Expense of Revenue |
9.67% | 11.84% | 7.81% | 9.36% | |
Selling, General and Administrative Expense of Revenue |
62.58% | 71.94% | 46.77% | 58.99% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
11.73% | 16.51% | 9.06% | 12.89% | |
Graham Net Nets |
0.06 | 0.07 | 0.06 | 0.06 | |
Graham Number |
8.85 | 8.24 | 7.12 | 6.11 | |
Earnings Yield |
1.08% | 1.34% | 0.89% | 0.83% | |
Free Cash Flow Yield |
2.71% | 2.91% | 1.37% | 1.28% | |
Revenue per Share |
1.52 | 1.35 | 1.85 | 1.34 | |
Operating CF per Share |
0.32 | 0.32 | 0.30 | 0.44 | |
Capex per Share |
(0.04) | (0.02) | (0.04) | (0.05) | |
Free Cash Flow per Share |
0.28 | 0.30 | 0.25 | 0.39 | |
Cash per Share |
3.18 | 2.86 | 2.73 | 2.68 | |
Shareholders Equity per Share |
7.25 | 7.02 | 7.04 | 6.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.25 | 7.02 | 7.04 | 6.37 | |
Free Cash Flow |
14.26 | 15.13 | 12.83 | 19.45 | |
Working Capital |
212.20 | 196.91 | 198.29 | 176.39 | |
Capital Expenditures |
(1.93) | (1.26) | (2.19) | (2.63) | |
Net Current Asset Value |
131.91 | 114.67 | 114.11 | 90.55 | |
EV/EBIT |
116.65 | 95.44 | 153.25 | 206.92 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.04 | |
Price to Operating Income |
124.61 | 103.56 | 164.14 | 223.54 | |
| Other line items | |||||
Average Receivables |
70.00 | 62.64 | 73.00 | 54.45 | |
Average Payables |
16.74 | 17.88 | 19.84 | 18.11 | |
Average Inventory |
17.61 | 17.73 | 17.47 | 16.96 | |
Average Assets |
469.24 | 455.11 | 460.35 | 421.84 | |
Average Common Equity |
338.43 | 325.86 | 323.30 | 289.67 |
Columns are period end dates